Levocetirizine Dihydrochloride is an H1 antihistamine (R-enantiomer of cetirizine) indicated for allergic rhinitis and chronic idiopathic urticaria. We supply it to US manufacturers of tablets and oral solution.
Data from PubChem (CID 9955977) and FDA’s substance registry
CAS number
130018-87-0
Molecular formula
C21H27Cl3N2O3
Molecular weight
461.8g/mol
FDA UNII
IUPAC name
2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid;dihydrochloride
InChIKey
PGLIUCLTXOYQMV-GHVWMZMZSA-N
- Appearance
- White or almost white powder.
- Solubility
- Freely soluble in water, and practically insoluble in acetone and methylene chloride.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
The R-enantiomer of cetirizine. The limit for the S-enantiomer is the figure to compare between sources.
On the US market
- Reference product
- XyzalNDA 022064
- Approved ANDAs
- 16 with a marketed product
- Approved forms and strengths
- Tablet 5 mg
- Oral solution 2.5 mg/5 mL
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com